NuCana

NuCana is a clinical-stage biopharmaceutical company developing a pipeline of cancer medicines using proprietary phosphoramidate prodrug chemistry.

Its approach transforms established nucleoside analogue chemotherapy agents into modified forms that bypass key tumour resistance mechanisms, delivering higher concentrations of active metabolite to cancer cells.

Pipeline candidates are in clinical trials for colorectal, pancreatic, biliary tract, and solid tumour indications. NuCana is headquartered in Edinburgh and listed on Nasdaq.